Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis

Safety and preliminary efficacy results of a randomized multicenter study

Norman Todd Ilowite, Oscar Porras, Andreas Reiff, Sue Rudge, Marilynn Punaro, Alan Martin, Roger Allen, Terry Harville, Yu Nien Sun, Terry Bevirt, Gary Aras, Brent Appleton

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

study assessed the safety and preliminary efficacy of the interleukin-1 receptor antagonist anakinra in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Eighty-six patients entered a 12-week open-label run-in phase (1 mg/kg anakinra daily, ≤100 mg/ day). Fifty responders were randomized to anakinra or placebo in a 16-week blinded phase, followed by a 12-month open-label extension (N = 44). Due to low enrollment, the primary endpoint was changed from efficacy to safety. The incidence and nature of adverse events were similar across all study phases, with the exception of injection site reactions, which were mild to moderate and decreased with time. Anakinra produced a nonsignificant (P = 0.11) reduction in disease flares compared with placebo. When normalized to 1 mg/kg dose, anakinra plasma concentrations were similar to values in adult patients with rheumatoid arthritis. These results indicate that anakinra 1 mg/kg once daily (≤100 mg/day) is safe and well tolerated in patients with JRA.

Original languageEnglish (US)
Pages (from-to)129-137
Number of pages9
JournalClinical Rheumatology
Volume28
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Juvenile Arthritis
Multicenter Studies
Safety
Therapeutics
Placebos
Interleukin-1 Receptors
Rheumatoid Arthritis
Injections
Incidence

Keywords

  • Anakinra
  • Interleukin-1
  • Interleukin-1receptor antagonist
  • Juvenile rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis : Safety and preliminary efficacy results of a randomized multicenter study. / Ilowite, Norman Todd; Porras, Oscar; Reiff, Andreas; Rudge, Sue; Punaro, Marilynn; Martin, Alan; Allen, Roger; Harville, Terry; Sun, Yu Nien; Bevirt, Terry; Aras, Gary; Appleton, Brent.

In: Clinical Rheumatology, Vol. 28, No. 2, 2009, p. 129-137.

Research output: Contribution to journalArticle

Ilowite, NT, Porras, O, Reiff, A, Rudge, S, Punaro, M, Martin, A, Allen, R, Harville, T, Sun, YN, Bevirt, T, Aras, G & Appleton, B 2009, 'Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: Safety and preliminary efficacy results of a randomized multicenter study', Clinical Rheumatology, vol. 28, no. 2, pp. 129-137. https://doi.org/10.1007/s10067-008-0995-9
Ilowite, Norman Todd ; Porras, Oscar ; Reiff, Andreas ; Rudge, Sue ; Punaro, Marilynn ; Martin, Alan ; Allen, Roger ; Harville, Terry ; Sun, Yu Nien ; Bevirt, Terry ; Aras, Gary ; Appleton, Brent. / Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis : Safety and preliminary efficacy results of a randomized multicenter study. In: Clinical Rheumatology. 2009 ; Vol. 28, No. 2. pp. 129-137.
@article{59604a9705fa4cb6a0fb829d5e246995,
title = "Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: Safety and preliminary efficacy results of a randomized multicenter study",
abstract = "study assessed the safety and preliminary efficacy of the interleukin-1 receptor antagonist anakinra in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Eighty-six patients entered a 12-week open-label run-in phase (1 mg/kg anakinra daily, ≤100 mg/ day). Fifty responders were randomized to anakinra or placebo in a 16-week blinded phase, followed by a 12-month open-label extension (N = 44). Due to low enrollment, the primary endpoint was changed from efficacy to safety. The incidence and nature of adverse events were similar across all study phases, with the exception of injection site reactions, which were mild to moderate and decreased with time. Anakinra produced a nonsignificant (P = 0.11) reduction in disease flares compared with placebo. When normalized to 1 mg/kg dose, anakinra plasma concentrations were similar to values in adult patients with rheumatoid arthritis. These results indicate that anakinra 1 mg/kg once daily (≤100 mg/day) is safe and well tolerated in patients with JRA.",
keywords = "Anakinra, Interleukin-1, Interleukin-1receptor antagonist, Juvenile rheumatoid arthritis",
author = "Ilowite, {Norman Todd} and Oscar Porras and Andreas Reiff and Sue Rudge and Marilynn Punaro and Alan Martin and Roger Allen and Terry Harville and Sun, {Yu Nien} and Terry Bevirt and Gary Aras and Brent Appleton",
year = "2009",
doi = "10.1007/s10067-008-0995-9",
language = "English (US)",
volume = "28",
pages = "129--137",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "2",

}

TY - JOUR

T1 - Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis

T2 - Safety and preliminary efficacy results of a randomized multicenter study

AU - Ilowite, Norman Todd

AU - Porras, Oscar

AU - Reiff, Andreas

AU - Rudge, Sue

AU - Punaro, Marilynn

AU - Martin, Alan

AU - Allen, Roger

AU - Harville, Terry

AU - Sun, Yu Nien

AU - Bevirt, Terry

AU - Aras, Gary

AU - Appleton, Brent

PY - 2009

Y1 - 2009

N2 - study assessed the safety and preliminary efficacy of the interleukin-1 receptor antagonist anakinra in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Eighty-six patients entered a 12-week open-label run-in phase (1 mg/kg anakinra daily, ≤100 mg/ day). Fifty responders were randomized to anakinra or placebo in a 16-week blinded phase, followed by a 12-month open-label extension (N = 44). Due to low enrollment, the primary endpoint was changed from efficacy to safety. The incidence and nature of adverse events were similar across all study phases, with the exception of injection site reactions, which were mild to moderate and decreased with time. Anakinra produced a nonsignificant (P = 0.11) reduction in disease flares compared with placebo. When normalized to 1 mg/kg dose, anakinra plasma concentrations were similar to values in adult patients with rheumatoid arthritis. These results indicate that anakinra 1 mg/kg once daily (≤100 mg/day) is safe and well tolerated in patients with JRA.

AB - study assessed the safety and preliminary efficacy of the interleukin-1 receptor antagonist anakinra in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Eighty-six patients entered a 12-week open-label run-in phase (1 mg/kg anakinra daily, ≤100 mg/ day). Fifty responders were randomized to anakinra or placebo in a 16-week blinded phase, followed by a 12-month open-label extension (N = 44). Due to low enrollment, the primary endpoint was changed from efficacy to safety. The incidence and nature of adverse events were similar across all study phases, with the exception of injection site reactions, which were mild to moderate and decreased with time. Anakinra produced a nonsignificant (P = 0.11) reduction in disease flares compared with placebo. When normalized to 1 mg/kg dose, anakinra plasma concentrations were similar to values in adult patients with rheumatoid arthritis. These results indicate that anakinra 1 mg/kg once daily (≤100 mg/day) is safe and well tolerated in patients with JRA.

KW - Anakinra

KW - Interleukin-1

KW - Interleukin-1receptor antagonist

KW - Juvenile rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=58149181586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149181586&partnerID=8YFLogxK

U2 - 10.1007/s10067-008-0995-9

DO - 10.1007/s10067-008-0995-9

M3 - Article

VL - 28

SP - 129

EP - 137

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 2

ER -